Thus, PD-1:PD-L1 immune checkpoint therapy using PD-1 antibodies (pembrolizumab and nivolumab) achieved great success in melanoma, bladder cancer, and gastric cancer therapy [9–11]. The gene discussed is PDCD1; the disease is urinary bladder carcinoma.